secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2025-02-18T23:59:59+00:00
Accession:  0000950170-25-022219
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC Pharma Q4/FY2024: $256M cash; R&D spend $114.1M; seven data readouts anticipated
--------------------------------------------------------------------------------

- Cash $256M as of Dec 31, 2024; expected to fund operations into late 2026.
- R&D expenses Q4 $32.0M (up 31% YoY), FY2024 $114.1M (up 34%).
- G&A expenses Q4 $7.6M (up 10%), FY2024 $28.8M (up 13%).
- Expects seven data readouts for ORIC-114, ORIC-944 over 18 months; potential registrational trials in 2H25/early 2026.
- Entered J&J collaboration for ORIC-114 + amivantamab in NSCLC; completed $125M private placement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000095017025022219/0000950170-25-022219-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000095017025022219/oric-20250218.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-022219

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer